2016 Minimal Residual Disease

 

The importance of MRD

MRD resources for researchers

Roundtable discussion: advances in MRD testing in myeloma

Minimal Residual Disease (MRD) is a hot topic today in the field of multiple myeloma (MM), in great part because we finally have very active treatment regimens that can bring deep and sustained responses to patients.

Download Slide Presentations:

Session I

Welcome: “Advances in minimal residual disease testing in myeloma – Presenter: Ola Landgren
New IMWG Response Criteria – Presenter: Shaji Kumar
Minimal Residual Disease assessment in Multiple Myeloma by Next-Generation Sequencing – Presenter: Ken Anderson
NCI-MSK collaboration: a formal MRD meta analysis – Presenter: Ola Landgren

Session II

Single tube 10-color assay for sensitive detection of residual plasma cell neoplasms: MSKCC experience – Presenter: Mikhail Roshal
New CAP requirements to improve MRD testing standardization – Presenter: Michael Linden
Towards detection of minimal residual disease in multiple myeloma through circulating tumour DNA sequence analysis – Presenter: Trevor Pugh
Comprehensive characterization of low abundance MM cells –in Blood and BM – Presenter: Jens Lohr

Lunch Session

Strategies in MRD for MM – Presenters: Ken Anderson & Daniel Auclair

Session III

Ongoing Trials – Presenter: Faith Davies
Next generation trials for MRD – Presenter: Ola Landgren

Session IV

MRD and High Risk Myeloma – Presenter: Gareth Morgan
MRD Implications for High risk Disease – Presenter: Rafael Fonseca
Clonal heterogeneity and MRD testing in multiple myeloma – Presenter: Sham Mailankody
Clonal Heterogeneity and MRD – Presenter: Jonathan Keats
Minimal residual disease in smoldering myeloma – Presenter: Malin Hultcrantz
MRD in the Transition of Smoldering MM to Symptomatic MM – Presenter: Christophe Heuck